Scientist Uses Lab-Grown Viruses to Treat Her Own Breast Cancer, Igniting Ethical Debate

In a groundbreaking yet ethically contentious move, virologist Beata Halassy reportedly treated her own breast cancer using lab-grown viruses, according to a case report published in the journal Vaccines. Halassy, aged 49, had been diagnosed in 2020 with recurrent stage 3 breast cancer at the site of a previous mastectomy. Rather than undergo another round of chemotherapy, she chose an unproven approach: oncolytic virotherapy (OVT), a cutting-edge treatment that utilizes viruses to attack cancer cells while triggering an immune response.

Reports indicate that Halassy, who is associated with the University of Zagreb, took matters into her own hands. Having extensive experience in virology, she decided to use her skills to cultivate viruses for a self-administered treatment. Over a two-month period, she injected her tumor with two types of lab-grown viruses, aiming to shrink the mass and mobilize her immune system against the cancer.

The self-treatment involved the sequential use of a modified measles virus followed by the vesicular stomatitis virus (VSV). Both of these viruses have a documented history of being safe for human use, with the measles strain frequently used in childhood vaccines and VSV known to cause, at worst, mild flu-like symptoms. The scientist relied on her research-grade viral preparations, which were freshly prepared and injected directly into her tumor by a colleague under clinical supervision.

As the treatment progressed, Halassy reportedly experienced a significant reduction in tumor size, with the mass detaching from surrounding tissues, thereby making surgical removal easier. An analysis conducted after the tumor’s surgical removal revealed a strong infiltration of immune cells, specifically lymphocytes, suggesting that the OVT had successfully triggered an immune response against the cancer cells. Post-surgery, Halassy underwent a year-long course of trastuzumab, an anticancer drug. She has been cancer-free for four years following this unconventional treatment.

Despite her success, Halassy faced numerous hurdles in getting her case published. Over a dozen scientific journals rejected her paper, citing ethical concerns. The primary issue, as noted by Jacob Sherkow, a legal expert at the University of Illinois Urbana-Champaign, was not the act of self-experimentation itself but the potential implications of publicizing such a case. There are fears that this could encourage other cancer patients to attempt similar unverified treatments, potentially leading them away from proven conventional therapies. Sherkow emphasized that while self-experimentation should not be a first-line approach, it remains important to preserve any valuable scientific knowledge it may yield.

Halassy’s decision to self-treat aligns her with a historical lineage of scientists who have engaged in self-experimentation. This practice has long been regarded with both admiration and skepticism. However, Halassy herself stressed that her choice to proceed with OVT was based on her specialized knowledge in virology rather than expertise in cancer treatment. She acknowledged that her bold move to self-medicate might have been a controversial one, underscoring the challenges she faced in getting her work published: “It took a brave editor to publish the report,” Halassy said.

OVT is still an emerging field in cancer therapy, designed to leverage viruses to target cancer cells while activating the immune system to enhance the body’s natural defenses. Although this treatment approach has gained approval for metastatic melanoma in the form of T-VEC in the United States, it has yet to secure approval for breast cancer or other early-stage cancers.

Stephen Russell, a specialist in oncolytic virotherapy, expressed both intrigue and caution regarding Halassy’s case. He acknowledged that the viral injections likely contributed to the tumor shrinkage but downplayed its significance as a groundbreaking advancement, since efforts to use OVT for earlier-stage cancers are already underway. Russell noted that the sequential use of two different viruses was a novel aspect of Halassy’s approach but argued that conclusions could not be definitively drawn from a single patient case.

The debate over Halassy’s case highlights the ethical gray areas surrounding self-experimentation in medical research. While her innovative approach may offer insights into new cancer therapies, the risks of encouraging unproven treatments among the general population remain a significant concern.

References:

1. "Revolutionizing Cancer Treatment with Oncolytic Virus Therapy." Nature, November 2024. Accessed November 27, 2024. https://www.nature.com/articles/d41586-024-03647-0.

2. "Oncolytic Virus Therapy." Cancer Research Institute. Accessed November 27, 2024. https://www.cancerresearch.org/treatment-types/oncolytic-virus-therapy.

(Input from various sources)

(Rehash/Ankur Deka/MSM)